Compugen (CGEN) Expected to Announce Earnings on Tuesday

Compugen (NASDAQ:CGEN) will likely be releasing its earnings data before the market opens on Tuesday, March 4th. Analysts expect Compugen to post earnings of $0.07 per share and revenue of $17.47 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Compugen Stock Down 1.4 %

NASDAQ:CGEN opened at $2.07 on Tuesday. The firm’s fifty day simple moving average is $2.00 and its 200-day simple moving average is $1.83. The stock has a market cap of $184.73 million, a PE ratio of 103.50 and a beta of 2.65. Compugen has a fifty-two week low of $1.35 and a fifty-two week high of $3.03.

Analysts Set New Price Targets

Separately, Oppenheimer initiated coverage on shares of Compugen in a research report on Monday, January 13th. They set an “outperform” rating and a $4.00 target price for the company.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.